Plain-English translation of NCT06632964 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called VT-101 for people with early-stage bladder cancer that has not invaded the muscle wall. VT-101 is a special virus designed to attack cancer cells while leaving healthy cells alone. The study will carefully increase the dose of this medication in small groups of patients to find the safest and most effective amount to use.
Current treatments for early-stage bladder cancer don't work well for everyone, and some patients face serious side effects or need surgery to remove their bladder. This trial is exploring whether this new virus-based treatment could offer another option that is both safer and more effective for people who need alternatives to standard care.
You likely qualify if…
You likely don't qualify if…
You would come to the hospital for weekly treatments over six weeks, where the medication is placed directly into your bladder through a catheter and left there for a period of time. After the initial six weeks, your doctor would decide whether to continue with monthly treatments for up to one year, depending on how well the treatment is working and how you are tolerating it. Throughout the trial, you would have regular check-ups, imaging scans, and urine tests to monitor your response to treatment and watch for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Collaborators
Xuzhou Medical University
Enrollment target
~16 participants
Started
September 2024
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hailong Li, M.D/Ph.D
The Affiliated Hospital of Xuzhou Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.